Clinical trial
A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of…
NCT00001031 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00001031 |
|---|---|
| Title | A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults |
| Official title | A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Biocine Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological |
| Interventions | rgp120/HIV-1MN, rgp120/HIV-1 SF-2 |
| Enrollment | 296 |
| Completion | Dec 1, 1997 |
| First posted | Aug 31, 2001 |
| Last update posted | Nov 4, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: